|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
BiOptix Inc has developed a highly-sensitive biosensor for detection of trace amounts (~pg/mm2) of bacteria, viruses, proteins, nucleic acids, antibodies and other biological and chemical agents in real-time and with minimal human intervention. Recently, BiOptix scientists used the prototype biosensor to detect clinically significant levels of human micro RNAs in experimental samples, opening an avenue for early and robust diagnostics of a variety of cancers. Illustration of the biodetector measurement principle The unique patented biosensor design relies upon the common path interferometric detection principle in combination with non-resonant surface plasmon excitation. This design was conceived by BiOptix Chief Scientific Adviser, Dr. John Hall, 2005 Physics Nobel Prize Laureate. A number of novel engineering decisions, described in the Technology section of our website, set BiOptix's biosensor far apart from the competition.
Antibodies immobilized on the surface of array-based chip capture biological material. Click on the image to see a Flash demo.
The new instrument has attracted significant interest from the US military, medical diagnostic industry, and pharmaceutical companies. Our R&D efforts are backed by seed funding from a group of highly experienced technology investors and multiple SBIR grants.
Preparations for our first round of venture capital funding are under way.
Please contact us to see how our new biodetector can help advance your business or research.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||